<DOC>
	<DOCNO>NCT00006039</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell slow growth non-Hodgkin 's lymphoma . PURPOSE : Phase II trial study effectiveness interferon alfa-2b treating patient advance low-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Interferon Alfa-2b Treating Patients With Advanced Low-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response patient minimally treat previously untreated advanced low-grade non-Hodgkin 's lymphoma treat pegylated interferon alfa-2b . II . Determine effect treatment regimen immune system measure T-cell subset NK cell patient population . III . Determine event-free progression-free survival patient population treat regimen . IV . Evaluate toxicity profile treatment regimen patient . OUTLINE : Patients receive pegylated interferon alfa-2b subcutaneously weekly 6 month absence disease progression unacceptable toxicity . Upon completion treatment , patient follow every 6 month least 2 year . PROJECTED ACCRUAL : A total 30 patient initially accrue study . Additional patient accrue acceptable response see first cohort .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade lymphoma include follow : REAL classification Follicular lymphoma ( grade I II ) Lymphoplasmacytoid lymphoma Small lymphocytic lymphoma Marginal Bcell lymphoma MALT lymphoma International Working Formulation Follicular small cleave cell lymphoma Follicular mix small large cell lymphoma Small lymphocytic lymphoma No intermediate highgrade nonHodgkin 's lymphoma ( NHL ) histology No evidence histologic transformation If previously untreated , large tumor burden include follow : Nodal extranodal mass great 7 cm diameter Involvement least 3 nodal site ( great 3 cm diameter ) Systemic symptom Splenomegaly Ureteral compression Intraabdominal stage II , stage III , stage IV disease Measurable disease No prior systemic therapy OR No 1 prior therapy ( e.g. , chemotherapy , immunotherapy , chemotherapy immunotherapy , chemotherapy regional radiotherapy ) A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC great 2,000/mm3 Absolute neutrophil count great 1,500/mm3 Platelet count great 75,000/mm3 Hemoglobin great 10 g/dL Absolute lymphocyte count great 5,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT/SGPT le 2.5 time ULN Alkaline phosphatase less 2.5 time ULN No active hepatitis Renal : Creatinine le 1.5 time ULN OR Creatinine clearance great 60 mL/min Cardiovascular : No severe cardiovascular disease No myocardial infarction within past 6 month No unstable angina No class III IV congestive heart failure No ventricular tachyarrhythmias Other : No active uncontrolled infection infection require systemic antibiotic HIV negative No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No history neuropsychiatric disorder require hospitalization Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 12 week since prior immunotherapy ( e.g. , rituximab ) No prior cytokine ( except filgrastim ( GCSF ) epoetin alfa ) Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>small intestine lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>